Bevacizumab
≥95%, ~25mg/ml(in buffer,PH6.2)
- Product Code: 103545
CAS:
216974-75-3
| Molecular Weight: | Molecular Formula: | ||
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20℃, away from light |
Product Description:
Bevacizumab is primarily used in the treatment of various types of cancers. It works by inhibiting the growth of blood vessels that supply tumors, effectively starving them of nutrients and oxygen. This makes it particularly effective in treating colorectal cancer, often in combination with chemotherapy. It is also used for non-small cell lung cancer, renal cell carcinoma, and glioblastoma.
In addition to cancer, Bevacizumab is utilized in treating certain eye conditions. It is effective in managing age-related macular degeneration, diabetic retinopathy, and macular edema. By reducing abnormal blood vessel growth in the retina, it helps prevent vision loss.
The drug is administered intravenously and requires careful monitoring due to potential side effects such as hypertension, bleeding, and impaired wound healing. Its targeted action on vascular endothelial growth factor (VEGF) makes it a valuable tool in both oncology and ophthalmology.
Product Specification:
| Test | Specification |
|---|---|
| Appearance | Liquid Or Solid |
| Purity (%) | 95-100 |
| Concentration | 25mg/ml |
| Ph | 6.0-6.3 |
| Note | This Product Contains Protective Fluid, May Change State In Different Temperature (Solid, Liquid Or Semi-Solid) |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.001 | 10-20 days | ฿15,000.00 |
+
-
|
| 0.005 | 10-20 days | ฿49,490.00 |
+
-
|
| 0.025 | 10-20 days | ฿123,740.00 |
+
-
|
Bevacizumab
Bevacizumab is primarily used in the treatment of various types of cancers. It works by inhibiting the growth of blood vessels that supply tumors, effectively starving them of nutrients and oxygen. This makes it particularly effective in treating colorectal cancer, often in combination with chemotherapy. It is also used for non-small cell lung cancer, renal cell carcinoma, and glioblastoma.
In addition to cancer, Bevacizumab is utilized in treating certain eye conditions. It is effective in managing age-related macular degeneration, diabetic retinopathy, and macular edema. By reducing abnormal blood vessel growth in the retina, it helps prevent vision loss.
The drug is administered intravenously and requires careful monitoring due to potential side effects such as hypertension, bleeding, and impaired wound healing. Its targeted action on vascular endothelial growth factor (VEGF) makes it a valuable tool in both oncology and ophthalmology.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :